- Home
- NXB vs TIL Comparison
NXB vs TIL Comparison
Compare NXB & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXB | TIL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 52.2M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NXB | TIL |
|---|---|---|
| Price | $2.26 | $7.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | ★ 65.2K | 5.8K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,866,298.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.08 | N/A |
| 52 Week Low | $1.79 | $5.67 |
| 52 Week High | $2.57 | $25.89 |
Technical Indicators
Market Signals| Indicator | NXB | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 44.93 |
| Support Level | $1.79 | $6.91 |
| Resistance Level | $2.29 | $7.50 |
| Average True Range (ATR) | 0.18 | 0.25 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 78.33 | 2.00 |
Price Performance
Historical ComparisonAbout NXB NextBoat Inc. Common Stcok
NextBoat Inc focused on AI-powered technology platform designed to modernize and scale the world-wide pre-owned marine marketplace.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.